SL1009 (sodium dichloroacetate)

Name: SL1009 (sodium dichloroacetate) in Pyruvate dehydrogenase complex deficiency: Expected outcomes of therapy
Published: 2026-09-14T15:39:06-04:00

Pyruvate dehydrogenase complex deficiency

Manufacturer: Saol Therapeutics
Regulatory submission: NDA resubmitted June 2026
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment

Expected outcomes of therapy

1 evidence topic · 1 source

Investigational biochemical outcome

“A key secondary endpoint measured the reduction in plasma lactate of SL1009 compared to placebo.” (opens the source at this quote in a new tab)